Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.
Samsung Bioepis’ Bevacizumab Filing Has Been Accepted By The FDA • Source: Shutterstock
Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen, has announced that its filing for a US biosimilar rival to Genentech’s Avastin (bevacizumab) has been accepted for review by the US Food and Drug Administration.
The biologics license application had been submitted by Samsung Bioepis
